• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results

    4/4/24 2:39:49 PM ET
    $ACHL
    $ALUR
    $CADL
    $EFTR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ACHL alert in real time by email

    U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday.

    The Dow traded down 0.59% to 38,894.58 while the NASDAQ fell 0.10% to 16,261.88. The S&P 500 also fell, dropping, 0.28% to 5,197.03.

    Check This Out: Insiders Buying Walgreens And 2 Other Stocks

     

    Leading and Lagging Sectors

     

    Communication services shares jumped by 1.1% on Thursday.

    In trading on Thursday, health care shares rose by just 0.1%.

     

    Top Headline

     

    Shares of RPM International Inc. (NYSE:RPM) fell more than 5% on Thursday after the company reported third-quarter FY24 results.

    Sales rose 0.4% Y/Y to $1.523 billion, slightly beating the consensus of $1.518 billion. Adjusted EPS of 52 cents exceeded the consensus of 46 cents.

     

    Equities Trading UP

     

    TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares shot up 59% to $2.0597. TCBP announced execution of non-binding letter of intent for acquisition of NK Platform Technologies.

    Shares of Allurion Technologies Inc. (NASDAQ:ALUR) got a boost, surging 101% to $3.46 after the company announced the commercial availability of its Virtual Care Suite in the United States. Also, Chardan Capital initiated coverage on the stock with a Buy rating and announced a $5 price target.

    Candel Therapeutics, Inc. (NASDAQ:CADL) shares were also up, gaining 113% to $3.57 after the company announced interim data from the randomized phase 2 clinical trial of CAN-2409 in non-metastatic prostate cancer.

     

    Equities Trading DOWN

     

    eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) shares dropped 81% to $3.1089. The company announced topline results from the primary analysis of the randomized Phase 2 KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer.

    Shares of Achilles Therapeutics plc (NASDAQ:ACHL) were down 24% to $0.9106 after the company reported fourth-quarter financial results. The company announced interim Phase I/IIa data on the use of clonal neoantigen reactive T cells from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer and the THETIS study in recurrent or metastatic malignant melanoma.

    KWESST Micro Systems Inc. (NASDAQ:KWE) was down, falling 21% to $0.89 after the company announced a proposed US public offering.

    Also Check This Out: Top 3 Real Estate Stocks That Are Ticking Portfolio Bombs

     

    Commodities

     

    In commodity news, oil traded up 1.4% to $86.59 while gold traded up 0.2% at $2,319.10.

    Silver traded up 1.2% to $27.39 on Thursday, while copper rose 1% to $4.2365.

     

    Euro zone

     

    European shares closed mostly higher today. The eurozone’s STOXX 600 rose 0.16%, London’s FTSE 100 rose 0.48% while Spain’s IBEX 35 Index rose 0.53% The German DAX rose 0.19% French CAC 40 fell 0.02% while Italy’s FTSE MIB Index fell 0.08%.

    Industrial producer prices in the eurozone fell by 1.0% from the prior month in February compared to a 0.9% decline in the prior month, while services PMI climbed to 51.5 in March versus 50.2 in the earlier month.

    The HCOB France services PMI fell to 48.3 in March versus 48.4 a month ago, while German services PMI rose to 50.1 in March versus a preliminary reading of 49.8. The S&P Global UK services PMI fell to 53.1 in March versus 53.8 in the prior month.

     

    Asia Pacific Markets

     

    Asian markets closed higher on Thursday, with Japan’s Nikkei 225 gaining 0.81% and India’s S&P BSE Sensex rising 0.5%.

    The HSBC Indian services PMI rose to 61.2 in March versus a preliminary reading of 60.3 and compared to a final reading of 60.6 in the prior month.

     

    Economics

     

    U.S. jobless claims rose by 11,000 from the previous week’s revised reading to 221,000 on March, the most in two months.

    U.S. trade deficit increased to $68.9 billion in February versus a revised $67.6 billion gap in the previous month.

    Now Read This: Levi Strauss, Conagra Brands And 3 Stocks To Watch Heading Into Thursday

     

    Get the next $ACHL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACHL
    $ALUR
    $CADL
    $EFTR

    CompanyDatePrice TargetRatingAnalyst
    RPM International Inc.
    $RPM
    1/9/2026$115.00Neutral → Overweight
    Analyst
    RPM International Inc.
    $RPM
    12/9/2025$132.00Sector Perform → Outperform
    RBC Capital Mkts
    Candel Therapeutics Inc.
    $CADL
    10/28/2025$15.00Overweight
    Stephens
    RPM International Inc.
    $RPM
    10/14/2025$129.00Neutral → Buy
    BofA Securities
    Candel Therapeutics Inc.
    $CADL
    9/3/2025$7.00Buy → Neutral
    BofA Securities
    RPM International Inc.
    $RPM
    8/14/2025$128.00Underperform → Neutral
    BofA Securities
    Candel Therapeutics Inc.
    $CADL
    6/30/2025$23.00Buy
    H.C. Wainwright
    RPM International Inc.
    $RPM
    6/2/2025$135.00Buy
    Citigroup
    More analyst ratings

    $ACHL
    $ALUR
    $CADL
    $EFTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Gibbons Brendan M. decreased direct ownership by 15% to 10,408 units (SEC Form 5)

    5 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    2/17/26 5:10:48 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Buch Ojas decreased direct ownership by 17% to 10,223 units (SEC Form 5)

    5 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    2/17/26 5:09:02 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Technology Officer Tyagarajan Seshu

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    1/28/26 5:04:50 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    $ALUR
    $CADL
    $EFTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds

    Allurion Technologies, Inc. (NYSE:ALUR) (the "Company" or "Allurion"), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,659,565 shares of common stock, issued by the Company on January 27, 2025 (the "January 2025 Warrants"), February 20, 2025 (the "February 2025 Warrants") and November 12, 2025 (the "November 2025 Warrants" and together with the January 2025 Warrants and the February 2025 Warrants, the "Existing Warrants"), at a reduced exercise price of $1.15 per share. The shares of common stock issuable upon exercise of the January 2025 Warra

    2/24/26 9:15:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston

    NEEDHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will present at TD Cowen's 46th Annual Health Care Conference, being held on March 2-4, 2026 in Boston, MA. Presentation Details: Date: Tuesday, March 3, 2026 Time: 11:50 AM - 12:20 PM ET Webcast Link: TD Cowen / Candel Presentation A webcast of the presentation will be available by selecting Events and Presentations under the News &

    2/24/26 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Allurion Receives U.S. FDA Approval

    Approval provides Allurion with access to approximately 80 million Americans with obesity Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval (PMA) application for the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule. "Today's approval is a watershed moment for Allurion and for obesity care in the United States," said Dr. Shantanu Gaur, Founder and Chief Executive Officer. "Our goal is to deliver patients metabolically healthy weight loss by helping them lose weight, keep it off, and maintain muscle. The Allurion Smart Capsule off

    2/23/26 9:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ACHL
    $ALUR
    $CADL
    $EFTR
    SEC Filings

    View All

    Allurion Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

    2/23/26 9:06:25 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by Candel Therapeutics Inc.

    8-K - Candel Therapeutics, Inc. (0001841387) (Filer)

    2/23/26 8:00:28 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by Candel Therapeutics Inc.

    424B5 - Candel Therapeutics, Inc. (0001841387) (Filer)

    2/20/26 4:16:14 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    $ALUR
    $CADL
    $EFTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Gaur Shantanu bought $24,484 worth of shares (8,000 units at $3.06), increasing direct ownership by 100% to 16,000 units (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    5/21/25 4:15:08 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Gaur Shantanu bought $26,800 worth of shares (8,000 units at $3.35) (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    4/1/25 4:15:07 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Director Manning Paul B bought $7,500,000 worth of shares (1,250,000 units at $6.00) (SEC Form 4)

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    12/18/24 4:11:47 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    $ALUR
    $CADL
    $EFTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RPM Inc upgraded by Analyst with a new price target

    Analyst upgraded RPM Inc from Neutral to Overweight and set a new price target of $115.00

    1/9/26 8:33:00 AM ET
    $RPM
    Paints/Coatings
    Consumer Discretionary

    RPM Inc upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded RPM Inc from Sector Perform to Outperform and set a new price target of $132.00

    12/9/25 8:35:22 AM ET
    $RPM
    Paints/Coatings
    Consumer Discretionary

    Stephens initiated coverage on Candel Therapeutics with a new price target

    Stephens initiated coverage of Candel Therapeutics with a rating of Overweight and set a new price target of $15.00

    10/28/25 8:02:46 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    $ALUR
    $CADL
    $EFTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by KWESST Micro Systems Inc.

    SC 13G - KWESST Micro Systems Inc. (0001889823) (Subject)

    11/14/24 5:34:02 PM ET
    $KWE
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

    SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

    11/14/24 4:43:43 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ACHL
    $ALUR
    $CADL
    $EFTR
    Leadership Updates

    Live Leadership Updates

    View All

    Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

    NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Bali Pulendran, Ph.D. to Candel's Research Advisory Board (RAB). Dr. Pulendran, an internationally recognized expert in systems immunology and vaccinology, who has pioneered the use of systems approaches to understand human immune responses, will bring his deep expertise to the RAB, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-311

    10/16/25 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board

    NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Carl H. June, M.D., to Candel's Research Advisory Board (RAB). Dr. June, an internationally recognized expert in cancer immunotherapy, and a pioneer in developing the first U.S. Food and Drug Administration (FDA)-approved CAR-T cell therapy, will bring Candel his deep expertise, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-3110 f

    9/2/25 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

    NEEDHAM, Mass., June 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Charles Schoch as Chief Financial Officer (CFO). Mr. Schoch, who has served as interim CFO of Candel since January 2024, will transition to the CFO role permanently, effective immediately. "Charles has demonstrated exceptional financial and organizational leadership during his tenure as interim CFO," said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. "He has effectively

    6/23/25 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    $ALUR
    $CADL
    $EFTR
    Financials

    Live finance-specific insights

    View All

    RPM Reports Fiscal 2026 Second-Quarter Results

    Record second-quarter sales of $1.91 billion, an increase of 3.5% compared to the prior-year record Second-quarter net income of $161.2 million, diluted EPS of $1.26, and EBIT of $229.0 million Second-quarter adjusted diluted EPS of $1.20, a decrease of 13.7% compared to the prior-year record and adjusted EBIT of $226.6 million, a decrease of 11.2% compared to the prior-year record Fiscal 2026 third-quarter outlook calls for mid-single-digit sales growth and adjusted EBIT to increase mid- to high-single digits Fiscal 2026 fourth-quarter outlook calls for mid-single-digit sales growth and adjusted EBIT to increase low- to high-single-digits Implementing SG&A-focused optimizat

    1/8/26 6:45:00 AM ET
    $RPM
    Paints/Coatings
    Consumer Discretionary

    RPM Declares Quarterly Dividend

    RPM International Inc. (NYSE:RPM) today announced that its board of directors declared a regular quarterly cash dividend of $0.54 per share, payable on January 30, 2026, to stockholders of record as of January 16, 2026. RPM's last cash dividend increase of 6% in October 2025 marked RPM's 52nd consecutive year of increased cash dividends paid to its stockholders, which places RPM in an elite category of less than half of 1 percent of all publicly traded U.S. companies. Only 39 other U.S. companies have consecutively paid an increasing annual dividend for a longer period of time, according to stockanalysis.com. During this timeframe, the company has returned approximately $3.8 billion in ca

    1/2/26 6:45:00 AM ET
    $RPM
    Paints/Coatings
    Consumer Discretionary

    RPM to Announce Fiscal 2026 Second-Quarter Results on January 8, 2026

    RPM International Inc. (NYSE:RPM) announced today that it will release its financial results for the fiscal 2026 second quarter before the stock market opens on Thursday, January 8, 2026. The results will be issued via newswire and will also be available on the RPM website at www.RPMinc.com. Management will host a conference call to discuss the results beginning at 10:00 a.m. Eastern Time the same day. The call can be accessed via webcast at www.RPMinc.com/Investors/Presentations-Webcasts/ or by dialing 844-481-2915, or 412-317-0708 for international callers. Participants are asked to call the assigned number approximately 10 minutes before the conference call begins and request to join th

    12/5/25 9:00:00 AM ET
    $RPM
    Paints/Coatings
    Consumer Discretionary